ALHC vs. CVS: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALHC and CVS, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
CVS towers over ALHC with a market cap of 78.57 billion USD, roughly 25.91 times the 3.03 billion USD of its peer.
ALHC rides a wilder wave with a beta of 1.33, hinting at bigger swings than CVS’s steadier 0.60.
| Symbol | ALHC | CVS |
|---|---|---|
| Company Name | Alignment Healthcare, Inc. | CVS Health Corporation |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Healthcare Plans | Medical - Healthcare Plans |
| CEO | Mr. John E. Kao | Mr. J. David Joyner CEBS |
| Price | 15.33 USD | 62.11 USD |
| Market Cap | 3.03 billion USD | 78.57 billion USD |
| Beta | 1.327 | 0.6 |
| Exchange | NASDAQ | NYSE |
| IPO Date | March 26, 2021 | November 20, 1996 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALHC and CVS over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALHC and CVS based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ALHC has a negative P/E of -32.75, indicating it’s been unprofitable over the past year with no net earnings to support its stock price. On the other hand, CVS at 14.83 has maintained positive earnings, showing a healthier profit profile.
- ALHC carries a negative Forward PEG of -1.11, hinting at analyst expectations of losses or shrinking earnings in the coming period—a potential warning for its future performance. On the flip side, CVS at 1.27 sidesteps this concern with a more favorable outlook.
| Symbol | ALHC | CVS |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -32.75 | 14.83 |
| Forward PEG Ratio (TTM) | -1.11 | 1.27 |
| Price-to-Sales Ratio (P/S, TTM) | 1.01 | 0.21 |
| Price-to-Book Ratio (P/B, TTM) | 27.45 | 1.02 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 159.00 | 13.23 |
| EV-to-EBITDA (TTM) | -64.47 | 10.98 |
| EV-to-Sales (TTM) | 0.86 | 0.40 |
| EV-to-Free Cash Flow (TTM) | 136.01 | 25.20 |
Dividend Comparison
ALHC pays no dividends, focusing all profits on growth, appealing to capital-gains investors. Meanwhile, CVS’s 4.28% yield rewards shareholders, showing financial confidence while supporting objectives—a contrast to ALHC’s growth-only approach.
| Symbol | ALHC | CVS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 4.28% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALHC and CVS, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- CVS’s current ratio of 0.82 dips below 1, leaving short-term liabilities larger than current assets—a scenario that could hinge on cash flow support. On the other hand, ALHC at 1.69 has enough assets to handle its obligations.
- At 0.63, CVS’s quick ratio falls below 0.8, where liquid assets, minus inventory, can’t keep up with short-term bills—possibly riding on cash flow. By contrast, ALHC hits 1.69, covering its bases comfortably.
- ALHC clocks in at -2.98 below 1.5, earnings just keeping ahead of interest—dicey if profits stumble. By contrast, CVS’s 3.18 sails through with plenty of cushion.
| Symbol | ALHC | CVS |
|---|---|---|
| Current Ratio (TTM) | 1.69 | 0.82 |
| Quick Ratio (TTM) | 1.69 | 0.63 |
| Debt-to-Equity Ratio (TTM) | 0.07 | 1.06 |
| Debt-to-Assets Ratio (TTM) | 0.01 | 0.32 |
| Interest Coverage Ratio (TTM) | -2.98 | 3.18 |